Australia’s federal health department is urging caution in using AI-powered medical scribing tools, highlighting risks around patient privacy, informed consent, and clinical accuracy as adoption nearly doubles among doctors.
- Use of AI scribes among Australian doctors rose from 22% in 2024 to 40% in 2025.
- Concerns include data privacy, patient consent, cloud data storage, and clinical documentation accuracy.
- Government to assess whether AI scribes should be regulated as medical devices.
What happened
The Australian federal health department and regulators have identified potential risks with the rapidly growing use of AI medical scribing tools. These AI systems automatically record, transcribe, and summarize doctor-patient interactions, aiming to reduce administrative burdens on healthcare providers. However, internal government documents reveal that these tools currently face minimal regulatory oversight despite their widespread clinical use.
Adoption of AI scribes in general practice nearly doubled from 22 percent in mid-2024 to 40 percent by late 2025 according to surveys, and industry platforms report processing hundreds of millions of consultations globally. While these tools promise productivity gains, authorities are concerned about data privacy, patient consent procedures, the transmission of sensitive health data internationally, and the accuracy and reliability of medical records created by AI.
Why it matters
AI scribes inherit many weaknesses from large language model technology, creating potential risks for patient safety and clinical accountability. Errors in transcription or summarization could lead to incorrect medical notes, affecting treatment decisions and digital health infrastructure quality. There are also significant privacy concerns as some providers send patient information to cloud servers outside Australia without sufficient transparency or patient knowledge.
Informed patient consent varies widely and at times appears inadequate, with reports that patients have been pressured to accept AI scribing or seek other providers. The government also questions claims that AI scribes can boost physician billing by 30 percent without increased workload, noting this could have implications for Australia’s publicly funded Medicare system and healthcare costs.
What to watch next
The Therapeutic Goods Administration (TGA) is currently evaluating whether AI medical scribe platforms should be classified as medical devices, a designation that would subject them to more rigorous regulation and safety standards. The review involves coordination among health, privacy, and professional regulatory bodies and is expected to yield recommendations in the upcoming months.
Stakeholders in Australia’s healthcare sector – including clinicians, patients, AI vendors, and regulators – will be closely monitoring the impact of these regulations on AI adoption and clinical workflows. The outcome will also influence how Australia balances innovation in healthcare efficiency with robust patient protections and responsible AI deployment.